03692 HANSOH PHARMA
- 18.080
- +0.080+0.44%
HANSOH PHARMA News
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Hansoh Pharmaceutical's 2023 Profit Up 27%
Hansoh Pharmaceutical Group (HKG:3692) recorded a 27% rise in attributable profit for 2023 to 3.28 billion yuan from 2.58 billion yuan in 2022, according to the company's annual report. Earnings per s
Hanson Pharmaceuticals (03692): Tan Sihui has been appointed as Joint Company Secretary
Hanson Pharmaceuticals (03692) announced that Li Xinying has resigned as the company's joint company secretary and will no longer serve as the Hong Kong Joint Stock Company...
Hanson Pharmaceuticals (03692) will pay a final dividend of HK$0.1422 per share on July 17
Hanson Pharmaceuticals (03692) announced that the company will pay a final dividend of 0 per share on July 17, 2024...
翰森製藥：2023年報
Featured announcements | CNOOC's net profit for the first quarter was nearly 40 billion yuan; China Aluminum's net profit for the first quarter increased 23.01% year-on-year
ZTE's net profit for the first quarter increased by 3.74% year on year; Times Electric's net profit for the first quarter increased by 30.44% year on year.
Hanson Pharmaceuticals (03692.HK) subsidiary signs licensing agreement with Quanxin Biotech
Hanson Pharmaceuticals (03692.HK) announced that on April 24, 2024, Hanson (Shanghai) Health Technology Co., Ltd. (licensee), a wholly-owned subsidiary of the company, signed a licensing agreement with Jiangsu Quanxin Biomedical Co., Ltd. (Quanxin Biotech).
Hanson Pharmaceuticals (03692.HK) to issue 2.3 million shares under restricted share unit plans
On April 19, GLONGHUI | Hanson Pharmaceuticals (03692.HK) announced that it will issue 2.3 million shares of the company on April 19, 2024 in accordance with the restricted share unit plan approved and adopted by the company on May 27, 2019.
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug
Hansoh Pharmaceutical Group (HKG:3692) said Chinese regulator NMPA has granted clinical trial approval for the group's HS10504 tablets, being developed to treat advanced, non-small-cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.
Hanson Pharmaceuticals (03692.HK): HS-10504 tablets received clinical trial notice
Gelonghui, April 3 | Hanson Pharmaceutical (03692.HK) announced that the Class 1 new drug HS-10504 tablets independently developed by the company's subsidiary Jiangsu Hausen Pharmaceutical Group Co., Ltd. and Shanghai Hanson Biomedical Technology Co., Ltd. have obtained a clinical trial notice approved and issued by the China National Drug Administration to treat advanced non-small cell lung cancer. The specific indications are to be determined after clinical trials.
Hanson Pharmaceuticals (3692.HK): Independent R&D and BD cooperation drive steady growth in the company's performance
The increase in revenue from innovative drugs and external licensing revenue led to a rapid increase in the company's profit growth rate in 2023. Independent research and development and BD cooperation form a differentiated pipeline layout. Maintain buying and raise DCF target price to HK$19.91 (W
Bank Rating | Citibank: Raising Hanson Pharmaceuticals Target Price to HK$28 to Maintain “Buy” Rating
Glonghui, March 29 | Citigroup released a report saying that Hanson Pharmaceuticals' revenue increased 7.7% year-on-year to 10.1 billion yuan last year, and net profit increased 26.9% year-on-year to 3.3 billion yuan. Management expects revenue contributions from innovative drugs to increase to 70% this year, and targets double-digit sales growth this year. The bank raised the company's revenue forecast for this year and next year by 8.6% and 2.7%, respectively, and raised earnings estimates by 29.5% and 15.4% per share. Its target price was raised from HK$25 to HK$28, maintaining its rating as “buy”.
Express News | Hanssen Pharmaceutical Group starts construction of global R&D headquarters in Shanghai
Hansoh Pharmaceutical Group Company Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Investors in Hansoh Pharmaceutical Group Company Limited (HKG:3692) had a good week, as its shares rose 4.2% to close at HK$15.48 following the release of its yearly results. It looks like a cre
Hanson Pharmaceuticals (3692.HK): Innovative drugs will lead steady revenue growth
Profit in 2023 exceeded expectations, and the company's revenue in 2023 increased 7.7% year-on-year to 10.14 billion yuan (RMB, same below). After excluding the milestone revenue of about 70 million yuan, pharmaceutical product sales revenue increased 1.1 billion year over year
Express News | Citi maintained Hanson Pharmaceuticals' “buy” rating and raised the target price to HK$28.
Analysis
Price Target
No Data
